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INTRODUCTION
Anemia is one of the most common complications in can-
cer patients, resulting from the suppression of hematopoiesis
by the cancer itself or therapeutic interventions, chronic nature
of the disease itself, recurrent infections due to suppressed
immunity, or impaired iron utilization (1, 2). Since anemia
adversely affects not only the patients' daily performance sta-
tus but also sensitivity to treatment and patients' prognosis
(3, 4), correction of the anemia is mandatory. Recently the
use of blood transfusion to correct anemia has been limited
because it is related to allergic hypersensitivity, transmission
of transfusion-mediated diseases, immune suppression, and
even to recurrence of cancer (5). 
Recombinant human erythropoietin (rhEPO) was first
shown to be effective for anemia of patients with chronic renal
failure in 1985, and since 1990, rhEPO has been tried for
the prevention or treatment of anemia in cancer patients. In
contrast to the chronic renal failure patients whose anemia
is due to the decreased production of erythropoietin (EPO),
anemic cancer patients responded to rhEPO only in 40-85%
(2, 6, 7). Although there have been reports that higher doses
of rhEPO could overcome the EPO resistance (2, 8), the eco-
nomic burden of rhEPO usage urged us to select proper can-
didates for the use of rhEPO. Knowledge of the factors affect-
ing hematopoiesis in anemic cancer patients might render
the more efficient use of rhEPO and, if there are any factors
that inhibit the EPO action, it might further suggest the way
to overcome those inhibitions. 
EPO is the most important factor for erythropoiesis pro-
duced in the kidney responding primarily to the tissue hypox-
ia and increases erythropoiesis by inducing proliferation of
erythroid precursors (9). Since the serum EPO level reflects
the accurate amount of EPO production (10), we can decide
whether the inadequate EPO production is the cause of ane-
mia by measuring the serum EPO. Soluble transferrin recep-
tor (sTfR), one of the parameters reflecting erythropoiesis,
rises before the increase of reticulocyte during active erythro-
poiesis, making it a useful index of early erythropoiesis (11).
Furthermore, unlike ferritin, sTfR is not influenced by inflam-
mation and therefore is useful to identify iron deficiency or to
evaluate erythropoiesis in chronic disease- or inflammation-
associated anemia (1). Although erythrocyte sedimentation
rate (ESR) has low sensitivity and specificity in detecting
the presence of disease, it is easy to measure and cost-effec-
tive, helping to screen the infection within a certain group
(12). Anemia in cancer patients is most commonly associat-
ed with the chronic nature of cancer itself and the chronic
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Defective Erythropoiesis in Bone Marrow is a Mechanism of Anemia
in Children with Cancer
Evaluation of the mechanism of anemia in cancer patients might help to select
patients for the more efficient use of erythropoietin (EPO, a growth factor for ery-
throid precursor cells). For this, we investigated whether the production of EPO
responds to anemia and the bone marrow responds to EPO appropriately, and
whether chronic inflammation is inhibitory to erythropoiesis in anemic cancer chil-
dren. Serum levels of EPO, soluble transferrin receptor (sTfR), tumor necrosis
factor (TNF)- , and erythrocyte sedimentation rate (ESR) in anemic cancer chil-
dren were measured by enzyme-linked immunosorbent assay and then the cor-
relation coefficients between those parameters and hemoglobin (Hb) were deter-
mined. Both in leukemia and in solid tumor patients, there were significant inverse
correlations between Hb and EPO (leukemia: tau=-0.547, p<0.0001; solid tumor:
tau=-0.591, p<0.0001), and between sTfR and EPO (leukemia: tau=-0.223, p<
0.05; solid tumor: tau=-0.401, p<0.05). In contrast, sTfR showed a correlation
with Hb in leukemia (tau=0.216, p<0.05) but not in solid tumor patients. sTfR was
suppressed in 53% of anemic episodes of leukemia and 78% of those of solid
tumor patients. Our results suggest that in cancer children, the EPO production is
not defective and chronic inflammation is not inhibitory to erythropoiesis. Rather,
the defective erythropoiesis itself is thought to be responsible for the anemia.  
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disease-associated anemia has known to be mediated by di-
verse cytokines (13). Increased cytokines in the chronic dis-
ease inhibits erythropoiesis by diverse ways from decreasing
not only EPO production but also marrow response to EPO
to inhibiting re-utilization of iron from the destroyed red
cells (13, 14). One prototypic cytokine of those is tumor ne-
crosis factor (TNF)- (15). 
The normal response to anemia of any cause is an increased
production of EPO from the kidney, which stimulates ery-
thropoiesis in the marrow to increase hemoglobin (Hb). If there
is any block in this process, anemia cannot be adequately com-
pensated. Since diverse factors interact within the normal ery-
thropoiesis, multiple factors might be responsible for the ane-
mia in cancer. In this study we determined the serum level
of EPO, sTfR, TNF- , and ESR in children with cancer with
or without anemia, to investigate the mechanism of anemia
and the factors responsible for the anemia in those children. 
MATERIALS AND METHODS
Peripheral blood samples were collected from 32 cancer
patients admitted to Korea University Medical Center for
chemotherapy. Samples were drawn once or twice from a
single patient if he/she was in different phases of treatment
and the sampling interval was at least more than 4 weeks.
Clinical characteristics of patients are shown in Table 1. Ane-
mia was defined as Hb level of less than 10 g/dL in either sex.
Hb was measured using Cell Dyn 4000 (Abbott, U.S.A.) in
an EDTA tube and erythrocyte sedimentation rate (ESR) was
measured using Sedimentic 100 (Analysis Instrument AB,
Sweden) in a sodium citrate tube. Serum EPO, sTfR, and
TNF- were measured by commercially available enzyme
immunoassay kits (EPO: Boehringer Mannheim, sTfR and
TNF- : R&D systems Inc.) following manufacturer's instruc-
tions. For statistical analyses of the data, Kendall rank corre-
lation coefficients between Hb and those parameters were
determined using StatView (Abacus Concepts, Inc.). 
RESULTS
Correlation coefficients between Hb and EPO, sTfR, TNF-
, or ESR and between sTfR and EPO, TNF- , or ESR in the
leukemia and solid tumor patients are summarized in Table 2. 
To investigate whether the EPO production is adequate in
anemic cancer patients, the correlations between EPO and
Hb were determined. There were moderate correlations bet-
ween Hb and EPO both in leukemia (tau=-0.547, p<0.0001)
and in solid tumor (tau=-0.591, p<0.0001) patients. sTfR,
an index of erythropoiesis, showed a weak correlation with
Hb in leukemia (tau=0.216, p<0.05) but not in solid tumor
(tau=0.184, p=0.2) patients. Since cancer itself is a chronic
disease and infection frequently occurs due to suppressed im-
munity in cancer, we investigated whether the chronic inflam-
mation is inhibitory to the erythropoietic activity of the bone
marrow in cancer patients. Neither TNF- nor ESR, as an
index of inflammation, showed a significant correlation with
Hb, EPO, or sTfR in leukemia or solid tumor patients. sTfR
Sex
Male 20 Hb<10 g/dL : 28
Hb>10 g/dL : 20
Female 12 Hb<10 g/dL : 18
Hb>10 g/dL : 12
Cancer type
Leukemia
ALL 21 Hb<10 g/dL : 28
Hb>10 g/dL : 21
AML 2 Hb<10 g/dL : 4
Hb>10 g/dL : 2
Solid tumor
Neuroblastoma 4 Hb<10 g/dL : 4
Hb>10 g/dL : 6
Brain tumor 2 Hb<10 g/dL : 5
Hb>10 g/dL : 2
Lymphoma 1 Hb<10 g/dL : 1
Hb>10 g/dL : 0
Pleuroblastoma 1 Hb<10 g/dL : 2
Hb>10 g/dL : 0
Osteosarcoma 1 Hb<10 g/dL : 2
Hb>10 g/dL : 1
ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia
Characteristics No. of patients No. of sampling
Table 1. Characteristics of the patients
EPO              
Low* High
� Low* High
�
Low
� 30 41
High
� 14 15 7 2            
Total 17 15 11 3
Low*: sTfR<20 nmol/L, High
� : sTfR>20 nmol/L, Low
� : EPO<100 U/L, High
�:
EPO>100 U/L, EPO: erytropoietin; sTfR: soluble transferrin receptor.
Leukemia
sTfR in
Solid tumor
Table 3. Distribution of serum EPO and sTfR levels in anemic
episodes (Hb<10) of leukemia and solid tumor patients
Hb, EPO -0.547* -0.591*
Hb, sTfR 0.216
� 0.184
Hb, TNF- -0.095 -0.175
Hb, ESR -0.122 -0.082
sTfR, EPO -0.223
� -0.401
�
sTfR, TNF- -0.016 0.029
sTfR, ESR 0.087 0.101
Hypothesized Correlation=0. *p-value<0.0001, 
� p-value<0.05.
Hb, hemoglobin; EPO, erythropoietin; sTfR, soluble transferrin receptor;
TNF- , tumor necrosis factor- .
Leukemia Solid tumor
Table 2. Correlation coefficients between parametersErythropoiesis and Anemic Cancer Children 339
representing erythropoietic activity inversely correlated with
the level of EPO in leukemia (tau=-0.223, p<0.05) and in
solid tumor (tau=-0.401, p<0.05) patients. To further char-
acterize the erythropoiesis in cancer patients, responses of
EPO and sTfR to anemia were determined. More than 100
U/L of EPO was defined as  “EPO responding to anemia"
(16, 17) and more than 20 nmol/L of sTfR was defined as
“marrow responding to anemia" (18). The results are sum-
marized in Table 3. In a total of 32 anemic episodes of leuke-
mia, both EPO and marrow responded to anemia in 15 epi-
sodes (47%), neither EPO nor marrow responded to anemia
in 3 episodes (9%), and EPO responded, but not marrow, in
14 episodes (43%). Conclusively in anemic leukemia patients,
EPO responded in 29 episodes (90%) and the marrow did
not respond in 17 episodes (53%). In a total of 14 anemic
episodes of solid tumor, both EPO and marrow responded to
anemia in 2 episodes (14%), neither EPO nor marrow re-
sponded in 4 episodes (28%), and EPO responded, but not
marrow, in 7 episodes (50%). In anemic solid tumor patients,
EPO responded in 9 episodes (64%) and the marrow did not
respond in 11 episodes (78%).
DISCUSSION
For rhEPO to be effective in anemic cancer patients, pre-
requisites such as inappropriate EPO production, normal re-
sponse of marrow to EPO, and no inhibitory effect of cyto-
kines to marrow are needed (19). Inappropriate EPO produc-
tion and/or impaired response of marrow to EPO have been
suggested as mechanisms of anemia in cancer patients (20-
24). Whether the EPO production in anemic cancer patients
is appropriate and, if there is an inappropriate EPO produc-
tion, whether the baseline serum EPO level can predict the
effectiveness of rhEPO in the presence of inappropriate EPO
production have been controversial (20-26). In our study,
EPO increased significantly in response to the decrease of Hb
in leukemia and solid tumor patients. The appropriateness of
this EPO response in anemic cancer patients can be judged
by comparing with the EPO level in iron deficiency anemia
(19, 27). Although we could not perform this comparison, a
significant moderate correlation between Hb and EPO in our
study seems to reflect an appropriate EPO response. In con-
trast to EPO, sTfR showed no or only a weak correlation with
Hb representing an impaired marrow response, in contrast
with the finding of iron deficiency anemia. 
The EPO response to anemia in cancer patients is shown to
be diverse, i.e., high, normal, or low. Besides anemia itself,
the level of EPO in cancer can be influenced by chemother-
apy. Ozguroglu et al. showed that EPO increased but not ade-
quately in anemic cancer patients and chemotherapy did not
influence the level of EPO (27). In contrast, Ludwig et al. re-
ported EPO increased during chemotherapy in leukemia and
solid tumor patients and a higher rhEPO level was needed
in the chemotherapy group than in the non-chemotherapy
group to increase the same degree of Hb (26). Furthermore,
Sawabe et al. described the increased level of absolute EPO
during chemotherapy and they explained that this was due
to the marrow suppressing effect from chemotherapy (28).
Since our study was performed on the patients admitted for
the chemotherapy, high EPO in our study might reflect the
sum of marrow responses to chemotherapy and to anemia. 
Pathophysiologically anemia can be divided into deficient
response of marrow (low sTfR/high EPO) and deficient pro-
duction of EPO (low sTfR/low EPO) (29). Since our study
showed low sTfR and high EPO, the anemia in our cancer
patients belongs to the former, coinciding with finding of
Corraza et al. (22). In spite of a significant inverse relation-
ship between Hb and EPO, Dowd et al. reported an inap-
propriately high or low EPO response to Hb in some cancer
patients, suggesting a possibility of another control mecha-
nism of EPO metabolism (23). Although the primary mech-
anism to control EPO is hypoxia due to low Hb, Cazzola et
al. showed that the serum level of EPO in reduced erythroid
mass is higher than that in the normal erythroid mass for
the same degree of low Hb. They speculated that this was
because of a difference in EPO use by erythroid mass, sug-
gesting the amount of erythroid mass in the bone marrow
as another mechanism to control serum EPO (30). Since sTfR
reflects the amount of erythroid mass, our study showing
low sTfR and high EPO can be due to decreased utilization
of EPO by the cancer itself- or treatment-induced reduced
erythroid mass as well as increased production of EPO by
responding to anemia. This is further supported by correla-
tions between EPO and sTfR both in leukemia and in solid
tumor patients in our study. 
One of the common causes of EPO resistance is infection
or inflammation (31); and diverse inflammatory cytokines
known to increase in cancer patient inhibit erythropoiesis
(4, 32). In contrast to this general belief, TNF- , a prototyp-
ic cytokine, and ESR, an index of inflammation, did not have
any correlation with Hb or sTfR in our study, suggesting that
the possibility of marrow suppression by TNF- of chronic
inflammation is unlikely. 
Bone marrow suppression represented by low sTfR was
shown in 53% of leukemia and 78% of solid tumor patients
(Table 3). Interestingly, sTfRs in a single patient varied from
high to low in different samples. If this is the case, the bone
marrow suppression may be reversible and high sTfR means
reactive bone marrow and deficient iron (18). Since 60% of
total iron is stored in red blood cells, only the presence of
anemia is enough to suggest the deficient storage of iron (26).
In addition, functional deficiency of iron in cancer patients
makes adequate iron supplementation mandatory to increase
the effect of rhEPO if used. 
In conclusion, our study demonstrated the EPO response
to anemia is adequate and chronic inflammation is not inhi-
bitory to erythropoiesis in children with cancer. Rather, the340 M.H. Kim, J.H. Lee, C.W. Wu, et al.
suppressed marrow seems to be related to anemia in those
children. Therefore the effectiveness of use of rhEPO with-
out indication for the prevention or treatment of anemia in
cancer is doubtful. For more effective use of rhEPO, careful
patient selection and adequate iron supplementation are need-
ed.
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